Bicara Therapeutics Inc. Current Income Tax Expense (Benefit)
Bicara Therapeutics Inc. (BCAX) reported Current Income Tax Expense (Benefit) of $217.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-30
- Bicara Therapeutics Inc. current income tax expense (benefit) for fiscal 2025 was $217.00K, a 16.04% increase from fiscal 2024.
- Bicara Therapeutics Inc. current income tax expense (benefit) for fiscal 2024 was $187.00K, a 3640.00% increase from fiscal 2023.
- Bicara Therapeutics Inc. current income tax expense (benefit) for fiscal 2023 was $5.00K.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $217.00K 10-K · filed 2026-03-30 | |
| 2024-12-31 | $187.00K 10-K · filed 2026-03-30 | $180.00K 10-K · filed 2025-03-27 |
| 2023-12-31 | $5.00K 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |